N01 CM 52202/CM/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2005	1
2006	3
2007	2
2008	2
2010	2
2011	1
2012	1
2013	2
2015	3
2024	0

1

Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.

Holleran JL, Beumer JH, McCormick DL, Johnson WD, Newman EM, Doroshow JH, Kummar S, Covey JM, Davis M, Eiseman JL. Holleran JL, et al. Cancer Chemother Pharmacol. 2015 Oct;76(4):803-11. doi: 10.1007/s00280-015-2857-x. Epub 2015 Sep 1. Cancer Chemother Pharmacol. 2015. PMID: 26321472 Free PMC article. Clinical Trial.

2

Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.

Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM, Egorin MJ. Beumer JH, et al. Clin Cancer Res. 2008 Jun 1;14(11):3529-35. doi: 10.1158/1078-0432.CCR-07-4885. Clin Cancer Res. 2008. PMID: 18519786

3

Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.

Beumer JH, Eiseman JL, Parise RA, Joseph E, Holleran JL, Covey JM, Egorin MJ. Beumer JH, et al. Clin Cancer Res. 2006 Dec 15;12(24):7483-91. doi: 10.1158/1078-0432.CCR-06-1250. Epub 2006 Nov 30. Clin Cancer Res. 2006. PMID: 17138702

4

Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.

Parise RA, Anyang BN, Eiseman JL, Egorin MJ, Covey JM, Beumer JH. Parise RA, et al. Cancer Chemother Pharmacol. 2013 Jan;71(1):73-83. doi: 10.1007/s00280-012-1980-1. Epub 2012 Oct 5. Cancer Chemother Pharmacol. 2013. PMID: 23053264 Free PMC article.

5

Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.

Holleran JL, Parise RA, Yellow-Duke AE, Egorin MJ, Eiseman JL, Covey JM, Beumer JH. Holleran JL, et al. J Pharm Biomed Anal. 2010 Sep 5;52(5):714-20. doi: 10.1016/j.jpba.2010.02.020. Epub 2010 Feb 23. J Pharm Biomed Anal. 2010. PMID: 20236781 Free PMC article.

6

Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection.

Beumer JH, Joseph E, Egorin MJ, Covey JM, Eiseman JL. Beumer JH, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):147-55. doi: 10.1016/j.jchromb.2005.11.048. Epub 2005 Dec 20. J Chromatogr B Analyt Technol Biomed Life Sci. 2006. PMID: 16364698

7

Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.

Beumer JH, Eiseman JL, Gilbert JA, Holleran JL, Yellow-Duke AE, Clausen DM, D'Argenio DZ, Ames MM, Hershberger PA, Parise RA, Bai L, Covey JM, Egorin MJ. Beumer JH, et al. Cancer Chemother Pharmacol. 2011 Feb;67(2):421-30. doi: 10.1007/s00280-010-1337-6. Epub 2010 May 5. Cancer Chemother Pharmacol. 2011. PMID: 20443002 Free PMC article.

8

Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.

Parise RA, Egorin MJ, Eiseman JL, Joseph E, Covey JM, Beumer JH. Parise RA, et al. Rapid Commun Mass Spectrom. 2007;21(13):1991-7. doi: 10.1002/rcm.3054. Rapid Commun Mass Spectrom. 2007. PMID: 17526067

9

A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice.

Beumer JH, Joseph E, Egorin MJ, Parker RS, D'argenio DZ, Covey JM, Eiseman JL. Beumer JH, et al. Clin Cancer Res. 2006 Oct 1;12(19):5826-33. doi: 10.1158/1078-0432.CCR-06-1234. Clin Cancer Res. 2006. PMID: 17020990

10

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).

Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ. Beumer JH, et al. Cancer Chemother Pharmacol. 2008 Jul;62(2):363-8. doi: 10.1007/s00280-007-0603-8. Epub 2007 Sep 26. Cancer Chemother Pharmacol. 2008. PMID: 17899082 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

13 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year